Skip to main content
SpringerLink
Log in

Behandlung von Herzerkrankungen mit AT1-Rezeptorantagonisten

  • Conference paper
Angiotensin II AT1-Rezeptorantagonisten

  • 23 Accesses

Zusammenfassung

Non-peptid-Angiotensin-II-Typ-l-(AT1)-Rezeptorantagonisten stellen eine Klasse von sehr wirksamen Medikamenten dar, die das Potential besitzen, die medikamentöse Therapie der arteriellen Hypertonie und der chronischen Herzinsuffizienz zu erweitern. Bei Patienten mit manifester arterieller Hypertonie ist die Langzeittherapie mit Losartan (50–200 mg/Tag) effektiv, um den Blutdruck auf physiologische Werte zu senken und pathologische Umbauprozesse („Remodeling“) im Myokard und dem Gefäßsystem zu verhindern. Bei chronischer Herzinsuffizienz zeigten experimentelle Untersuchungen und Studien mit Patienten nach Myokardinfarkt, daß die Therapie mit dem Non-peptid-AT1-Rezeptorantagonisten Losartan (25–100 mg/Tag) nahezu äquipotent ist im Vergleich zu ACE-Inhibitoren (beispielsweise Enalapril 20 mg/Tag).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baumann G (1996) ACE Inhibition after Myocardial Infarction. In: Tan LB, Ball SG (eds) ACE Inhibition. Science Press Limited, London, pp 7–12

    Google Scholar 

  2. Bedecs K, Elbaz N, Sutren M, Masson M, Susinin C, Strosberg D, Nahimias C (1997) Angiotensin II Type 2 receptor mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phopshtase. Biochem J 325: 449–454

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Bunkenburg B, van Amelsvooit T, Rogg H, Wood JM (1992) Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle eels from spontaneously hypertensive rats. Hypertens 20: 746–754

    Article  CAS  Google Scholar 

  4. Crozier I, Ikram H, Awan N (1995) Losartan in heart failure: hemodynamic effects and tolerability. Circuladon 91: 691–697

    Article  CAS  Google Scholar 

  5. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J (1995) Comparison of the effects of Losartan and Enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438–445

    Article  CAS  PubMed  Google Scholar 

  6. Dickstein K, Gotdieb S, Fleck E, Kosds J, Levine B, Dock M, Lemtel T (1994) Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens Suppl 12: 31–35

    Google Scholar 

  7. Gohlke P, Pees C, Unger T (1998) AT2 receptor stimulation increases aortic MP in SHRSP by a kinin- dependent mechanism. Hypertension 31: 349–355

    Article  CAS  PubMed  Google Scholar 

  8. Gotdieb SS, Dickstein K, Fleck E, Kosds J, Levine TB, Lemtel T, Dock M (1993) Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circuladon 88: 1602–1609

    Article  Google Scholar 

  9. Ishida M, Marrero MB, Schieffer B, Bernstein KE, Berk BC (1995) Angiotensin II acdvates pp60c-src in vascular smooth muscle cells. Circ Res 77: 645–651

    Article  Google Scholar 

  10. Johnston CI (1993) Angiotensin Converdng Enzyme Inhibition. In: Robertson JIS, Nichols MG (eds) The renin angiotensin system. Gower Medical Publication, pp 87.1–87.15

    Google Scholar 

  11. Johnston CI (1995) Angiotensin receptor antagonist: focus on losartan. Lancet 346: 1403–1407

    Article  CAS  PubMed  Google Scholar 

  12. Keidar S, Kaplan M, Hofman A, Aviram M (1995) Angiotensin II stimulates macrophage-mediated oxidation of low-density lipotproteins. Atherosclerosis 115: 201–215

    Article  CAS  PubMed  Google Scholar 

  13. Keidar S, Atdas J, Smith J, Breslow J, Hayek T (1997) The angiotensin II receptor antagonist, Losartan, inhibits LDL lipid perxodadon and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Com 236: 622–625

    Article  CAS  PubMed  Google Scholar 

  14. Levy D, Garrison RJ, Savage DD, Kanel WB, Castelli WP (1990) Prognostic implicadons of echocardio- graphically determined left ventricular mass in the framigham study N Engl J Med 322: 1561–1566

    CAS  Google Scholar 

  15. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE (1995) The angiotensin II type 1 receptor associates with and sdmulates JAK2 in rat aortic smooth muscle cells. Nature 375: 247–250

    Article  CAS  PubMed  Google Scholar 

  16. Marrero MB, Schieffer B, Paxton WG, Schieffer E, Bernstein KE (1995) Electroporation of pp60c-src antibodies inhibits the angiotensin II acdvation of phospholipase-cl in rat vascular smooth muscle cells. J Biol Chem 270: 15734–15738

    Article  CAS  PubMed  Google Scholar 

  17. Milavetz JJ, Raya TE, Johnson C, Morkin E, Goldmann S (1996) Survival after myocardial infarction in rats: Captopril versus losartan. J Am Col Cardiol 27: 714–719

    Article  CAS  Google Scholar 

  18. Pitt B, Segal R, Martinez FA for the ELITE Invesdgators (1997) Randomized trial of losartan versus Captopril in patinets over 65 with heart failure (Evaluadon of Losartan in the Elderly Study [ELITE]). Lancet 349: 747–752

    Article  CAS  PubMed  Google Scholar 

  19. Regitz-Zagrosek V, Neuss M, Fleck E (1995) Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Europ Heart J 16: 86–91

    Article  CAS  Google Scholar 

  20. Ruzicka M, Yuan B, Leenen FHH (1994) Effects of Enalapril versus Losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 90: 484–491

    Article  CAS  PubMed  Google Scholar 

  21. Schieffer B, Wirger A, Meybrunn M, Seitz, Neragi S, Holtz J, Riede UN, Drexler H (1994) Comparadve effects of chronic ACE-inhibidon and ATI-blockade on cardiac remodeling after myocardial infaction. Circuladon 89: 2273–2282

    Article  CAS  Google Scholar 

  22. Schieffer B, Wollert KC, Berchtold M, Saal K, Hornig B, Schieffer E, Riede UN, Drexler H (1995) Development and prevendon of skeletal muscle structural alteradons in experimental chronic heart failure. Am J Physiol 269: H1507-H1513

    CAS  PubMed  Google Scholar 

  23. Schieffer B, Paxton WG, Bernstein KE, Marrero MB (1996) Angiotensin II controls p21 ras activity via pp60csrc in vascular smooth muscle cells. J Biol Chem 271: 10329–10333

    Article  CAS  PubMed  Google Scholar 

  24. Schieffer E, Herrmann G, Müller B, Günther R, Simon R, Studer R, Drexler H (1996) Expression of Angiotensin II forming enzymes in artherosclerotic human coronary arteries: selektive upregulation in unstable angina. Europ Heart J (Suppl 1): 2274

    Google Scholar 

  25. Schieffer B, Pax ton WG, Marrero MB, Bernstein KE (1996) Importance of tyrosine phosphorylation in Angiotensin II ATI receptor mediated signalling. Hypertension 27: 476–480

    Article  CAS  PubMed  Google Scholar 

  26. Schieffer B, Wyrwoll F, Wollert KC, Brauer N, Drexler H (1997a) Angiotensin II enhances the expression and release of interleukin-6 in human coronry smooth muscle cells: Involvement of the Jak-Stat pathway. Circulation Vol 97 (Suppl. II): -P635

    Google Scholar 

  27. Schieffer B, Wyrwoll F, Marrero MB, Drexler H (1997b) Gβ-Subnunit connects the JAK/STAT pathway via gpl30 and the p21ras/MAP Kinase cascade via SHC in angiotensin II stimulated vascular smooth muscle cells. Circulation 97 (Suppl. II): P773

    Google Scholar 

  28. Smits JFM, van Krimpen C, Schoemakers RG, Cleutjens JPM, Daemen MJAP(1992) Angiotensin II Receptor Blockade after Myocardial Infarction in Rats: Effect on Hemodynamics, Myocardial DNA Synthesis and Interstitial Collagen Content. J Cardiovasc Res 20: 272–278

    Google Scholar 

  29. Stoll M, Steckelings UM, Paul M, Bottari S, Metzger R, Unger T (1994) The angiotensin AT2-receptor mediates inhibition of coronary endothelial cells. J Clin Invest 95: 651–657

    Article  Google Scholar 

  30. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF (1991) Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12: 55–62

    Article  CAS  PubMed  Google Scholar 

  31. Timmermanns PBMWM, Wong PC, Chiu AT, Duncia JV (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205–230

    Google Scholar 

  32. Urata H, Boehm K, Philip A (1993) Human chymase: cellular localization and regional distribution of a major angiotensin Il-forming enzyme in the heart. J Clin Invest 91: 1269–1281

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Whelton PK (1994) Epidemiology of Hypertension, Lancet 344: 101–104

    Article  CAS  PubMed  Google Scholar 

  34. Wollert KC, Studer R, Kästner S, Doerfer K, Schieffer E, Holubarsch C, Just HJ, Drexler H (1997) Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium. Circulation 95: 1910–1917

    Article  CAS  PubMed  Google Scholar 

  35. Yonezawa T, Umemoto S, Fujii A, Katayama K, Matzsaki M (1996) Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J Cardiovasc Pharmacol 27: 119–124

    Article  CAS  PubMed  Google Scholar 

  36. Zierhut W, Studer R, Laurent D, Kästner S, Allegrini P, Whitebread S, Cumin F, Baum HP, de Gasparo M, Drexler H (1996) Left ventricular wall stress and sarcoplasmatic reticulum Ca2-h-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and ATI-receptor blockade. J Cardiovasc Res 31: 758–768

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Kardiologie und Angiologie, Zentrum Innere Medizin Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    Prof. Dr. H. Drexler

Authors
  1. B. Schieffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. H. Drexler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Med. Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Deutschland

    Peter Dominiak

  2. Institut für Pharmakologie, Klinikum der Christian-Albrechts-Universität zu Kiel, Hospitalstraße 4, D-24105, Kiel, Deutschland

    Thomas Unger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Schieffer, B., Drexler, H. (1999). Behandlung von Herzerkrankungen mit AT1-Rezeptorantagonisten. In: Dominiak, P., Unger, T. (eds) Angiotensin II AT1-Rezeptorantagonisten. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93705-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93705-7_5

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-93706-4

  • Online ISBN: 978-3-642-93705-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation